Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXA-REFINE
2024-519759-27-00Phase 4Authorised
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexamethasone in Acute hypoxaemic respiratory failure (AHRF) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Centro de Investigación Biomédica en Red. Primary endpoint: All-cause hospital mortality. Planned start Dec 2024; status: authorised.
02
Drugs
dexamethasone
03
Conditions
Acute hypoxaemic respiratory failure (AHRF)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-519759-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519759-27-00.